Showing results (91-100 of 154) with videos related to

Sort By:
Pageof 16
RSC Medicinal Chemistry|July 31, 2025
Microwave-assisted synthesis of tubulin assembly inhibitors as anticancer agents by aryl ring reversal and conjunctive approachDomiziana Masci, Michela Puxeddu, Claudia Colla, et al.
Pharmaceuticals (Basel, Switzerland)|October 23, 2021
Discovery of a Novel Class of Norovirus Inhibitors with High Barrier of ResistanceJana Van Dycke, Michela Puxeddu, Giuseppe La Regina, et al.
Cells|November 11, 2020
Targeting the Interaction between the SH3 Domain of Grb2 and Gab2Francesca Malagrinò, Antonio Coluccia, Marianna Bufano, et al.
European Journal of Medicinal Chemistry|April 29, 2014
New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitorsValeria Famiglini, Giuseppe La Regina, Antonio Coluccia, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 15, 2015
Violacein, an indole-derived purple-colored natural pigment produced by Janthinobacterium lividum, inhibits the growth of head and neck carcinoma cell lines both in vitro and in vivoLaura Masuelli, Fabrizio Pantanella, Giuseppe La Regina, et al.
Journal of Medicinal Chemistry|August 29, 2018
Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus ReplicationLaurène Da Costa, Els Scheers, Antonio Coluccia, et al.
Journal of Medicinal Chemistry|February 3, 2006
New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studiesGabriella De Martino, Michael C Edler, Giuseppe La Regina, et al.
Journal of Medicinal Chemistry|May 26, 2006
Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamideRino Ragno, Antonio Coluccia, Giuseppe La Regina, et al.
European Journal of Medicinal Chemistry|October 15, 2011
1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for the design of either CB1 or CB2 receptor ligandsFrancesco Piscitelli, Alessia Ligresti, Giuseppe La Regina, et al.
Pageof 16